AEON Biopharma, Inc.

AEON Biopharma, Inc. (NYSE American: AEON) is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination with Priveterra Acquisition Corp in mid-2023, with an 8-K filed on June 30, 2023 marking a key closing milestone. The blank-check vehicle, sponsored by Priveterra Sponsor LLC, conducted its initial public offering in 2021 targeting the healthcare sector. The combined company focuses on the development of botulinum toxin-based therapeutics for medical indications. Following the merger, AEON Biopharma began trading on NYSE American as the surviving public entity. Sign up for full data on SpacDesk to access complete filing timelines, sponsor profiles, and deal analytics for AEON and the broader SPAC universe.